Immunic (IMUX) Cash from Investing Activities (2013 - 2026)
Immunic (IMUX) posted Cash from Investing Activities of -$2000.0 for Q1 2026, up 81.82% sequentially from -$11000.0 in Q4 2025, and up 95.74% YoY from -$1021.7 in Q1 2025.
Powered by 
Analysis
Immunic (IMUX) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Immunic has reported Cash from Investing Activities for 14 years, with the latest figure at -$2000.0 in Q1 2026.
- Quarterly Cash from Investing Activities rose 95.74% year-over-year to -$2000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$116000.0 (up 58.57% YoY) and the FY2025 annual result came in at -$161000.0, up 39.02% from the prior year.
- Cash from Investing Activities grew to -$2000.0 in Q1 2026 per IMUX's latest filing, from -$11000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $5.3 million in Q1 2023 and troughed at -$9.6 million in Q4 2022.
- A 5-year average of -$41529.4 and a median of -$36000.0 in 2025 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities tumbled 50573.68% in 2022, then soared 44558.33% in 2023.
- Over 5 years, Cash from Investing Activities stood at -$9.6 million in 2022, then soared by 98.29% to -$165000.0 in 2023, then surged by 98.18% to -$3000.0 in 2024, then plunged by 266.67% to -$11000.0 in 2025, then jumped by 81.82% to -$2000.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$2000.0, -$11000.0, and -$67000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Immunic | 546.30 Mn | 546.30 Mn | - | -249,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -249,000.00 |
| Mar 31, 2026 | -2,000.00 |
| Dec 31, 2025 | -11,000.00 |
| Sep 30, 2025 | -67,000.00 |
| Jun 30, 2025 | -36,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Sep 30, 2024 | -50,000.00 |
| Jun 30, 2024 | -180,000.00 |
| Mar 31, 2024 | -31,000.00 |
| Dec 31, 2023 | -165,000.00 |
| Sep 30, 2023 | -44,000.00 |
| Jun 30, 2023 | 4.34 Mn |
| Mar 31, 2023 | 5.34 Mn |
| Dec 31, 2022 | -9.63 Mn |
| Sep 30, 2022 | -73,000.00 |
| Jun 30, 2022 | -28,000.00 |
| Mar 31, 2022 | -12,000.00 |
| Dec 31, 2021 | -19,000.00 |
| Sep 30, 2021 | -20,000.00 |